Oseltamavir: Difference between revisions

(11 intermediate revisions by 4 users not shown)
Line 1: Line 1:
==General==
==General==
*Type:  
*Type: Antiviral - neuraminidase inhibitor
*Dosage Forms:
*Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL)
*Common Trade Names:  
*Common Trade Names: Tamiflu


==Adult Dosing==
==Adult Dosing==
Line 10: Line 10:
==Pediatric Dosing==
==Pediatric Dosing==
''5 day course''
''5 day course''
*1-8 months: 3 mg/kg PO BID
*1-8 months: 3mg/kg PO BID
*9-23 months: 3.5 mg/kg PO BID
*9-23 months: 3.5mg/kg PO BID
*2-12 years:
*2-12 years:
**<15kg: 30 mg PO BID
**<15kg: 30mg PO BID
**16-23kg: 45 mg PO BID
**16-23kg: 45mg PO BID
**24-40kg: 60 mg PO BID
**24-40kg: 60mg PO BID
**>40kg: 75 mg PO BID
**>40kg: 75mg PO BID


==Special Populations==
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: Category C
*Lactation:
*Lactation: Unknown; caution required
*Renal Dosing
*Renal Dosing
**Adult
**Adult
Line 33: Line 33:
==Adverse Reactions==
==Adverse Reactions==
===Serious===
===Serious===
Rare <1%
Arrhythmia, delirium, hemorrhagic colitis, hepatitis, seizure, TEN, SJS, angioedema, unstable angina, pseudomembranous colitis


===Common===
===Common===
Abdominal pain, insomnia, nausea, vomitting, vertigo, epistaxis, ear complaints, conjunctivitis.


==Pharmacology==
==Pharmacology==
*Half-life:  
*Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate)
*Metabolism:  
*Metabolism: hepatic
*Excretion:  
*Excretion: urine/stool
*Mechanism of Action:
*Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes.


==See Also==
==See Also==


==Sources==


==References==
<references/>
<references/>
[[Category:Drugs]]
 
[[Category:Pharmacology]]

Revision as of 03:50, 1 November 2017

General

  • Type: Antiviral - neuraminidase inhibitor
  • Dosage Forms: capsule (30, 45, 75mg), powder for PO susp (6mg/mL)
  • Common Trade Names: Tamiflu

Adult Dosing

Influenza

75mg PO BID x5d

Pediatric Dosing

5 day course

  • 1-8 months: 3mg/kg PO BID
  • 9-23 months: 3.5mg/kg PO BID
  • 2-12 years:
    • <15kg: 30mg PO BID
    • 16-23kg: 45mg PO BID
    • 24-40kg: 60mg PO BID
    • >40kg: 75mg PO BID

Special Populations

  • Pregnancy Rating: Category C
  • Lactation: Unknown; caution required
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

Rare <1%

Arrhythmia, delirium, hemorrhagic colitis, hepatitis, seizure, TEN, SJS, angioedema, unstable angina, pseudomembranous colitis

Common

Abdominal pain, insomnia, nausea, vomitting, vertigo, epistaxis, ear complaints, conjunctivitis.

Pharmacology

  • Half-life: 1-3 hrs (oseltamivir); 6-10hrs oseltamivir carboxylate)
  • Metabolism: hepatic
  • Excretion: urine/stool
  • Mechanism of Action: competitive inhibition of influenza virus neuraminidase enzyme, effectively halting viral release from infected cells and passing through mucus membranes.

See Also

References